Dayton Misfeldt
2019
In 2019, Dayton Misfeldt earned a total compensation of $339.9K as Interim CEO at Sunesis Pharmaceuticals, a 41% decrease compared to previous year.
Compensation breakdown
| Option Awards | $299,886 |
|---|---|
| Other | $40,000 |
| Total | $339,886 |
Misfeldt received $299.9K in option awards, accounting for 88% of the total pay in 2019.
Misfeldt also received $40K in other compensation.
Rankings
In 2019, Dayton Misfeldt's compensation ranked 12,693rd out of 13,971 executives tracked by ExecPay. In other words, Misfeldt earned more than 9.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 12,693 out of 13,971 | 9th |
Division Manufacturing | 5,133 out of 5,701 | 10th |
Major group Chemicals And Allied Products | 2,016 out of 2,200 | 8th |
Industry group Drugs | 1,736 out of 1,886 | 8th |
Industry Pharmaceutical Preparations | 1,285 out of 1,398 | 8th |
Source: SEC filing on April 28, 2020.
Misfeldt's colleagues
We found two more compensation records of executives who worked with Dayton Misfeldt at Sunesis Pharmaceuticals in 2019.